Evidence map›Paper›PMID 37154970›Full record

ArticleAnnals of surgical oncology2023

Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients.

Eiji Shinto, Eiji Oki, Mototsugu Shimokawa, Shigeki Yamaguchi, Megumi Ishiguro, Seiji Hasegawa, Yasumasa Takii, Hideyuki Ishida, Tetsuya Kusumoto, Masaru Morita and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Eiji ShintoDepartment of Surgery, National Defense Medical College, Tokorozawa, Japan. eiji-c@zf6.so-net.ne.jp.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Shigeki YamaguchiDepartment of Surgery, Division of Colorectal Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Megumi IshiguroMedical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.
Seiji HasegawaDepartment of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
Yasumasa TakiiDepartment of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Hideyuki IshidaDepartment of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Tetsuya KusumotoDepartment of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Masaru MoritaDepartment of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Naohiro TomitaCancer Treatment Center, Toyonaka Municipal Hospital, Toyonaka, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Masafumi TanakaColoproctology Center, Takano Hospital, Kumamoto, Japan.
Heita OzawaDepartment of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan.
Yojiro HashiguchiDepartment of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Shinobu OhnumaDepartment of Surgery, Tohoku University Hospital, Sendai, Japan.
Sachiyo TadaLS Business, Sysmex Corporation, Kobe, Japan.
Tomoko MatsushimaLS Business, Sysmex Corporation, Kobe, Japan.
Keisuke YamagishiLS Business, Sysmex Corporation, Kobe, Japan.
Kazuo HaseDepartment of Surgery, National Defense Medical College, Tokorozawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA molecular budding signature (MBS), which consists of seven tumor budding-related genes, was recently presented as a prominent prognostic indicator in colon cancer (CC) using microarray data acquired from frozen specimens. This study aimed to confirm the predictive power of MBS for recurrence risk based on formalin-fixed, paraffin-embedded (FFPE) materials.

methodsThis research utilized the same microarray data from a prior multicenter study using FFPE whole tissue sections, which retrospectively reviewed 232 stage II CC patients without adjuvant chemotherapy and 302 stage III CC patients with adjuvant chemotherapy. All patients underwent upfront curative surgery without neoadjuvant therapy between 2009 and 2012. An MBS score was calculated using the mean of log2 [each signal] of seven genes (MSLN, SLC4A11, WNT11, SCEL, RUNX2, MGAT3, and FOXC1) as described before.

resultsThe MBS-low group exhibited a better relapse-free survival (RFS) than the MBS-high group in stage II (P = 0.0077) and in stage III CC patients (P = 0.0003). Multivariate analyses revealed that the MBS score was an independent prognostic factor in both stage II (P = 0.0257) and stage III patients (P = 0.0022). Especially among T4, N2, or both (high-risk) stage III patients, the MBS-low group demonstrated markedly better RFS compared with the MBS-high group (P = 0.0013).

conclusionsThis study confirmed the predictive power of the MBS for recurrence risk by employing FFPE materials in stage II/III CC patients.

Indexed as

Colonic NeoplasmsNeoplasm Recurrence, LocalAnion Transport ProteinsAntiportersChemotherapy, AdjuvantHumansNeoplasm StagingPrognosisRetrospective StudiesAnion Transport ProteinsAntiportersSLC4A11 protein, human

Identifiers

PMID37154970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.